Skip to main content
Back
Watch Compare

Aquestive Therapeutics, Inc.

Data quality: 100%
AQST
Nasdaq Manufacturing Chemicals
$4.17
▼ $0.02 (-0.36%)
Mkt Cap: 508.32 M
Price
$4.17
Mkt Cap
508.32 M
Day Range
$4.12 — $4.21
52-Week Range
$2.12 — $7.55
Volume
490,028
Open $4.12
50D / 200D Avg
$3.95
5.46% above
50D / 200D Avg
$4.81
13.38% below

Quick Summary

Key Takeaways

Revenue declined -3.25% annually over 5 years
Negative free cash flow of -52.99 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 19.36%
Capital efficient — spends only 1.26% of revenue on capex

Growth

Revenue Growth (5Y)
-3.25%
Below sector avg (1.82%)
Revenue (1Y)-22.61%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROIC-53.83%
Net Margin-188.09%
Op. Margin-159.50%

Safety

Debt / Equity
N/A
Current Ratio5.93
Interest Coverage-6.39

Valuation

PE (TTM)
-6.07
Below sector avg (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -6.1 -1.5
P/B — 1.6
ROE % — -53.5
Net Margin % -188.1 -41.5
Rev Growth 5Y % -3.3 1.8
D/E — 0.3

ETFs Holding This Stock

BRSIX BRSIX
0.47% weight
GSSC logo GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF
0.03% weight
IIRSX IIRSX
0.02% weight
IRSIX IRSIX
0.02% weight
IRCIX IRCIX
0.02% weight
VVICX VVICX
0.02% weight
IRSSX IRSSX
0.02% weight
IWV logo IWV iShares Russell 3000 ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -22.61% Revenue Growth (3Y) -6.16%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -3.25% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 44.55 M Net Income (TTM) -83.78 M
ROE N/A ROA -65.14%
Gross Margin N/A Operating Margin -159.50%
Net Margin -188.09% Free Cash Flow (TTM) -52.99 M
ROIC -53.83% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5.93
Interest Coverage -6.39 Asset Turnover 0.35
Working Capital 126.10 M Tangible Book Value -4.11 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -6.07 Forward P/E N/A
P/B Ratio N/A P/S Ratio 11.41
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -10.43%
Market Cap 508.32 M Enterprise Value 424.25 M
Per Share
EPS (Diluted TTM) -0.78 Revenue / Share 0.37
FCF / Share -0.43 OCF / Share -0.43
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1.26% FCF Conversion 63.25%
SBC-Adj. FCF -60.82 M Growth Momentum -19.36

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 44.55 M 57.56 M 50.58 M 47.68 M 50.83 M
Net Income -83.78 M -44.14 M -7.87 M -54.41 M -70.54 M
EPS (Diluted) -0.78 -0.51 -0.13 -1.12 -1.85
Gross Profit — — — — —
Operating Income -71.05 M -30.77 M -15.10 M -42.07 M -34.68 M
EBITDA — — — — —
R&D Expenses 17.19 M 20.28 M 13.10 M 17.48 M 17.05 M
SG&A Expenses 79.85 M 50.18 M 31.75 M 52.88 M 53.48 M
D&A 548,000.0 718,000.0 1.35 M 2.39 M 2.96 M
Interest Expense 11.12 M 11.12 M 6.34 M 6.55 M 10.05 M
Income Tax 0.0 -14,000.0 245,000.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 160.43 M 101.42 M 57.42 M 57.07 M 61.99 M
Total Liabilities 194.09 M 161.58 M 163.91 M 175.62 M 144.13 M
Shareholders' Equity -33.66 M -60.16 M -106.49 M -118.55 M -82.13 M
Total Debt 45.00 M 45.00 M 45.00 M — —
Cash & Equivalents — — — — —
Current Assets 149.27 M 88.22 M 40.97 M 39.89 M 47.26 M
Current Liabilities 47.61 M 18.87 M 18.31 M 39.53 M 21.96 M